Ann: Azer-cel Hits Major Milestone in Phase 1b CAR T Trial, page-203

I am getting a picture of IMU's competitive advantages over possibly other up and coming bio techs other than the breakthrough drugs/treatments/medical techs:
- Experts in their respective fields, LC mentioned something about only hiring the best in an interview
- Experts with track records in getting products to markets
- Methodologies in carrying out trials and progressing along FDA requirements
- Capital raising in difficult capital markets in the midst of multiple economic and geopolitical instabilities
- Abilities to spot opportunities and synergies and ACT on them

I am sure there are always rooms for improvement, especially unsolicited suggestions from die-hard shareholders at certain public forum...

They say never fall in love with a stock, but oh boy my old heart is getting that queasy feelings I first felt in high school towards a few classmates and the odd teacher.

Never financial advice, just m usings so please dyor.
glta.